Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Fulvestrant (Primary) ; Erlotinib; Gefitinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LADIE
- 07 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
- 09 Mar 2016 Planned End Date changed from 1 May 2019 to 1 Dec 2018, according to ClinicalTrials.gov record.